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DCs and NK cells are important elements of 
the innate immune system in its relationship 
to the ultimate response of the adaptive im-
mune system to infl  ammatory insults. The fi  rst 
contact between immature DCs (iDCs) and 
antigens occurs in peripheral tissue at sites of 
infl  ammation where iDCs are recruited from 
the bloodstream through cytokine and chemo-
kine signals produced by resident DCs and 
other cell types (1, 2). After antigen uptake, 
iDCs undergo a maturation process that al-
lows the resulting mature DCs (mDCs) to mi-
grate to secondary lymphoid tissues, where 
they prime an antigen-specifi  c T cell response. 
In the past few years, NK cells have been found 
to be extremely important in optimizing the 
diff  erentiation of mDCs. This process requires 
both NK cell–DC (NK–DC) cellular inter-
actions and NK cell secretion of specifi  c cyto-
kines. The fi  nal outcome of this cross talk is the 
coordination and optimization of both the in-
nate and adaptive immune responses (1–6).
DCs undergoing maturation secrete sev-
eral cytokines, such as IL-12 and -15, that act 
as potent inducers of NK cell activation and 
proliferation. In turn, once activated, NK cells 
produce IFN-γ, TNF-α, and GM-CSF, three 
important antiviral cytokines that are directly 
involved in completing the maturation pro-
gram of DCs (1–3, 5, 7–10). The incomplete or 
aberrant maturation of DCs is highly undesir-
able because antigen presentation by these cells 
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In this study, we demonstrate that the in vitro interactions between a CD56neg/CD16pos 
(CD56neg) subset of natural killer (NK) cells and autologous dendritic cells (DCs) from HIV-
1–infected viremic but not aviremic individuals are markedly impaired and likely interfere 
with the development of an effective immune response. Among the defective interactions 
are abnormalities in the process of reciprocal NK–DC activation and maturation as well as 
a defect in the NK cell–mediated editing or elimination of immature DCs (iDCs). Notably, 
the lysis of mature DCs (mDCs) by autologous NK cells was highly impaired even after the 
complete masking of major histocompatibility complex I molecules, suggesting that the 
defective elimination of autologous iDCs is at the level of activating NK cell receptors. In 
this regard, the markedly impaired expression/secretion and function of NKp30 and TNF-
related apoptosis-inducing ligand, particularly among the CD56neg NK cell subset, largely 
accounts for the highly defective NK cell–mediated lysis of autologous iDCs. Moreover, 
mDCs generated from HIV-1 viremic but not aviremic patients are substantially impaired in 
their ability to secrete interleukin (IL)-10 and -12 and to prime the proliferation of neigh-
boring autologous NK cells, which, in turn, fail to secrete adequate amounts of 
interferon-𝗄.
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might lead to T cell tolerance or apoptosis and, therefore, to a 
greatly impaired adaptive immune response (11, 12). NK cells 
further optimize conditions for subsequent T cell priming by 
eliminating DCs that have failed to mature properly. iDCs 
express remarkable amounts of classic HLA-A/-B/-C mol-
ecules but at considerably lower levels compared with mDCs 
(13, 14). Moreover, very low levels of expression of non-
classic HLA-E on surfaces of iDCs compared with mDCs have 
also been reported (15). The attenuated expression of MHC-I 
molecules, the natural ligands for the inhibitory NK receptors 
(iNKRs), makes iDCs uniquely susceptible to NK cell lysis 
(1, 16). NK cell–mediated killing of iDCs likely occurs to a 
substantial degree only when these two cell types colocalize 
in suffi   cient numbers at sites of tissue infection/infl  ammation 
(2, 5, 12, 17). Therefore, in their interactions with DCs, NK 
cells can act as regulatory cells as well as eff  ectors to ensure an 
appropriate activation of adaptive immunity (12).
Several lines of evidence suggest that normal NK–DC 
  interactions are aberrant in HIV-1 infection. A recent study 
showed that the autologous NK cell lysis of immature monocyte-
derived DCs (MDDCs [iMDDCs]) generated from HIV-1–
infected individuals was defective; however, the mechanisms 
underlying this phenomenon have not yet been elucidated 
(18). In addition, diff  erent studies showed that the expression 
and function of several important activating and inhibitory 
NK cell receptors are altered in viremic HIV-1–infected indi-
viduals (19–22). Furthermore, NK cells isolated from viremic 
patients exhibit defective cytotoxicity (20, 21) and cytokine 
secretion (23) after activation. All of these phenotypic and 
functional NK cell abnormalities are particularly pronounced 
in an unusual CD56neg/CD16pos (CD56neg) NK cell subset that 
is preferentially expanded in HIV-1–infected individuals with 
high levels of active viral replication and are rarely represented 
in aviremic patients or in healthy donors (20, 23–25).
Both ex vivo and in vitro studies have shown that during 
the course of HIV-1 infection, several functional defects are 
associated with mDCs, although their surface expression of 
maturation markers appears to be normal. These defects in-
clude an impaired ability to prime autologous CD4+ T cells 
and a decreased secretion of several cytokines and chemo-
kines despite a retained antigen uptake capacity (26–30). 
These phenotypic and functional perturbations observed in 
HIV-1–exposed NK cells and DCs strongly suggest that there 
might be abnormalities in the interactions between these two 
important members of the innate immune system (31).
This study characterizes the highly impaired bidirectional 
NK–DC cross talk in chronically HIV-1–infected viremic 
individuals compared with HIV-1 seropositive patients whose 
viremia had been suppressed to undetectable levels by anti-
retroviral therapy (ART) and with normal uninfected control 
Figure 1.  mDC functional profi  les and ability to prime autologous 
NK cells. (A and B) Levels of IL-12p70 (A) and IL-10 (B) secreted by mDCs 
generated from healthy donors (HD; yellow bars), HIV-1–infected avire-
mic (green bars) patients, and viremic (red bars) HIV-1–infected patients. 
(C) Levels of IFN-γ secreted by freshly purifi  ed NK cells cocultured with 
autologous mDCs (yellow bars) for 24 h. mDCs alone (blue bars) and NK 
cells alone (red bars) served as negative controls. The mDC/NK cell ratio 
was 1:10. (D) mDC-mediated priming of NK cells; fresh NK cells (responders) 
purifi  ed from HIV-1–infected viremic (red triangles) and aviremic 
(green squares) individuals and from uninfected subjects (yellow circles) 
were cocultured with autologous mDCs (stimulators) at different ratios. 
Cells were harvested after 4 d of coincubation, and the proliferation of 
NK cells was measured by 3[H]thymidine incorporation. All data are pre-
sented as the median (± SD [error bars] for A–C) of experiments con-
ducted on 15 healthy donors and 15 HIV-1 viremic and aviremic infected 
patients.JEM VOL. 203, October 2, 2006  2341
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subjects. We also demonstrate that the phenotypic and func-
tional characteristics of the CD56neg NK cell subset present at 
high frequencies in viremic individuals underlie the highly 
dysfunctional interactions between NK cells and DCs.
RESULTS
Phenotypic correlates of DC maturation
Previous studies have demonstrated that the exposure of iDCs 
generated in vitro from healthy donors to various strains of 
HIV-1 or to HIV-1–Gp120 envelope before exposure to 
maturation stimuli results in the impairment of several mDC 
functions despite the normal expression of surface markers 
associated with a mature phenotype (28–30). On the basis 
of these studies, we sought to determine whether iDCs ob-
tained from HIV-1–infected patients expressed normal levels 
of those surface markers that usually defi  ne an mDC when 
exposed to strong maturation stimuli. The evaluation of 
CD40, CD80, CD83, CD86, MHC-I, and MHC-II surface 
expression on in vitro–generated iDCs after 24 h in culture 
with LPS (the time frame within which maturation occurs) 
did not reveal substantial diff  erences among viremic and 
aviremic HIV-1–infected patients or uninfected individuals 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20060894/DC1). Similar experimental results were ob-
tained when triggering the maturation of iDCs with sCD40 
ligand (unpublished data).
Functional correlates of mDCs
Despite the expression of cell surface markers associated with 
a mature phenotype, we found that mDCs derived from vi-
remic patients exhibited several functional defects that could 
potentially impair the mDC-mediated activation of NK cells. 
In vitro matured DCs from viremic HIV-1–infected subjects 
secreted a markedly lower amount of IL-10 as well as IL-12, 
which is an important cytokine for the activation of NK cells 
(7–9, 32), compared with mDCs of HIV-1–infected aviremic 
patients who were receiving ART (for IL-10) or with healthy 
donors (for IL-10 and -12; Fig. 1, A and B). However, the 
production of IL-15 and -18 by mDCs did not substantially 
diff  er among the three study groups (unpublished data).
To determine the capacity of mDCs to activate immuno-
regulatory functions of NK cells, we measured the amount of 
IFN-γ secreted by NK cells in the presence of autologous 
mDCs. As shown in Fig. 1 C, resting NK cells from HIV-1–
infected aviremic patients released IFN-γ in amounts compa-
rable with those from uninfected donors. In contrast, freshly 
purifi  ed NK cells cocultured with autologous mDCs derived 
from viremic individuals showed a statistically signifi  cant 
lower secretion of IFN-γ (P < 0.001). Moreover, within 
the same group of viremic individuals, the ability to secrete 
IFN-γ was markedly lower (P < 0.001) in freshly purifi  ed 
CD56neg NK cells compared with CD56pos/CD16pos (CD56pos) 
NK cells (unpublished data). We could not detect substantial 
diff  erences in the levels of TNF-α and GM-CSF secreted by 
NK cells or NK cell subsets primed with autologous mDCs 
among the three study groups (unpublished data).
As previously described, an important function of mDCs 
is to trigger the proliferation/activation of autologous resting 
NK cells (1–3, 5). In coculture experiments, the ability of 
mDCs generated from viremic patients to induce the prolif-
eration of autologous NK cells was signifi  cantly diminished 
compared with that of either HIV-1–infected aviremic indi-
viduals (P < 0.001) or uninfected donors (P < 0.001; Fig. 1 D). 
This result was not likely caused by an inherent defect in 
the proliferative capacity of NK cells isolated from viremic 
patients because these cells displayed a normal proliferation in 
response to mDCs derived from aviremic HIV-1–infected or 
healthy subjects in heterologous cocultures. Furthermore, 
NK cells isolated from all HIV-1–infected or uninfected sub-
jects exhibited signifi  cantly lower rates of proliferation when 
cultured with heterologous mDCs generated from viremic 
subjects compared with proliferation rates triggered by expo-
sure to heterologous mDCs generated from healthy donors 
Figure 2.  mDC priming of heterologous NK cells. Fresh NK cells 
(responders) purifi  ed from HIV-1–infected viremic (red triangles) and 
aviremic (green squares) individuals and from healthy donors (HD; yellow 
circles) were cocultured with heterologous mDCs (stimulators) generated 
from healthy donors (A) as well as aviremic (B) and viremic (C) HIV-1–
infected individuals at different ratios. Cells were harvested after 4 d of 
coincubation, and the proliferation of NK cells was measured by 
3[H]thymidine incorporation. Data are presented as the median of experi-
ments conducted on 15 healthy donors and 15 HIV-1 viremic and avire-
mic infected patients.2342  NK CELL–DC DEFECTIVE CROSS TALK IN HIV-1 INFECTION | Mavilio et al.
(P < 0.001) or HIV-1–infected aviremic individuals (P < 
0.001; Fig. 2). Therefore, these coculture experiments con-
fi   rm that the defective NK cell proliferation observed in 
HIV-1–infected viremic patients was not caused by a primary 
impairment of NK cell responsiveness but by an impairment 
of the triggering of NK cells by mDCs.
To address whether mDCs had any role in the expansion 
of the CD56neg NK cell subset, we analyzed the distribution 
of CD56 and CD16 on the surface of NK cells cocultured 
with heterologous mDCs. Under all combinations of DC 
and NK cell cocultures, mDCs were not able to modify the 
relative distribution of NK cell subsets. In particular, heterol-
ogous cocultures of DCs generated from HIV-1–infected vi-
remic patients and NK cells purifi  ed from healthy donors did 
not result in the expansion of the CD56neg NK cell subset 
(unpublished data).
NK cell–mediated killing of autologous iDCs
A recent study showed that iMDDCs from HIV-1–infected 
patients are relatively resistant to killing by autologous NK 
cells (18). To ascertain whether this phenomenon pertains to 
all HIV-1–infected individuals or is restricted to those with 
high levels of chronic HIV-1 viremia, we analyzed the base-
line lysis of autologous iDCs by rIL-2–activated, unfraction-
ated NK cells isolated from HIV-1 viremic and aviremic 
patients. The degree of NK cell–mediated lysis of autologous 
iDCs was calculated using the traditional Cr51 release assay 
and was also visualized by fl  uorescence microscopy (Fig. S2, 
available at http://www.jem.org/cgi/content/full/jem.
20060894/DC1). Spontaneous killing of autologous iDCs 
by activated NK cells isolated from aviremic patients did 
not substantially diff   er from that observed with NK cells 
  purifi  ed from healthy donors. In contrast, the elimination of 
autologous iDCs by NK cells isolated from HIV-1–infected 
viremic individuals was markedly reduced compared with 
that from either aviremic HIV-1–infected subjects or healthy 
controls. This result was not likely caused by an increased re-
sistance of iDCs to the elimination by NK cells from HIV-1–
infected viremic patients. As shown in Fig. 3 A, the 
susceptibility to NK cell–mediated killing of heterologous 
Figure 3.  NK cell–mediated killing of heterologous iDCs and au-
tologous MHC-I masked mDCs. (A) Cytolysis exerted by unfractionated 
rIL-2–activated NK cells purifi  ed from a healthy donor, an aviremic, and 
a viremic HIV-1–infected individual against heterologous iDCs generated 
from a healthy donor (HD; yellow bars), an aviremic (green bars), and 
a viremic (red bars) HIV-1–infected patient. (B) Autologous mDC cytolysis 
exerted by unfractionated rIL-2–activated NK cells purifi  ed from a healthy 
donor (yellow bars), an aviremic (green bars), and a viremic (red bars) HIV-1–
infected individual. (C) Comparison of autologous mDC killing exerted by 
rIL-2–activated CD56pos- (dark blue bars) and CD56neg (light blue bars)-
derived NK cell subsets purifi  ed from the same HIV-1–infected viremic 
subject shown in B. NK cells were incubated either in the absence (base-
line lysis) or presence of specifi  c mAbs masking classic HLA-A/-B/-C and 
nonclassic HLA-E. Data were obtained from single experiments performed 
in triplicate (± SD [error bars]) and are representative of results obtained 
using cells isolated from 15 viremic and 15 aviremic HIV-1–infected indi-
viduals and from 15 healthy donors. The NK cell/iDC ratio in all experi-
ments was 10:1.JEM VOL. 203, October 2, 2006  2343
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iDCs isolated from all HIV-1–infected or uninfected subjects 
did not diff  er if cocultured with NK cells purifi  ed either from 
aviremic or healthy individuals. Only NK cells purifi  ed from 
viremic patients displayed a markedly defective killing of 
  heterologous iDCs isolated from all HIV-1–infected or un-
infected donors.
Using NK cells isolated from viremic individuals, we fur-
ther characterized the defect in NK cell–mediated lysis of 
iDCs by comparing rIL-2–activated CD56neg- and CD56pos-
derived NK cell subsets for their ability to eliminate autolo-
gous iDCs. The iDC killing appeared to be relatively intact 
for the CD56pos NK cell subset but was highly impaired for 
the CD56neg subpopulation (Fig. S2).
Cellular mechanisms of the impaired NK cell–mediated 
killing of autologous iDCs
For an NK cell to exert lytic activity, an inhibitory signal 
must be weak or lacking, and an activating signal must be 
present. The interactions between MHC-I molecules and 
iNKRs trigger an inhibitory signal and result in the abroga-
tion of NK cell lytic activity even if activating NK cell recep-
tors are triggered. Two major classes of MHC-I–specifi  c 
surface inhibitory receptors have been identifi   ed on NK 
cells: (a) the killer cell Ig-like receptors (KIRs), which bind 
HLA/-B/-C alleles, and (b) CD94/NKG2A, which binds to 
nonclassic HLA-E alleles (33–35). In this regard, the lysis of 
autologous iDCs is confi  ned to the subpopulation of NK 
cells that express CD94/NKG2A and lack KIRs (36). More-
over, NKp30, one of the three natural cytotoxicity receptors, 
has been shown to be primarily responsible for the NK cell–
mediated killing of autologous iDCs (16).
Role of MHC-I molecules
Under physiological conditions, the maturation of DCs leads to 
the elevated surface expression of classic and nonclassic MHC-I 
molecules that render them resistant to NK cell–mediated 
  cytolysis (1, 2, 5). As expected, the normal levels of HLA-A/
-B/-C and HLA-E (Fig. S1) expressed by mDCs generated 
from donors in all three study groups made them similarly re-
sistant to lysis by activated NK cells. Given the importance of 
interactions between MHC-I and iNKRs in inhibiting the NK 
cell–mediated killing of autologous mDCs (1, 2, 5), the mask-
ing of HLA molecules using specifi  c mAbs would theoreti-
cally enhance the susceptibility of mDCs to lysis by NK cells 
in vitro. Despite the complete blocking of all HLA-I alleles with 
specifi  c mAbs, activated NK cells from viremic patients were 
still highly impaired in their cytolytic activity against autolo-
gous mDCs compared with NK cells from aviremic patients 
and uninfected individuals. Moreover, the cytotoxicity of the 
rIL-2–activated CD56neg-derived NK cell subset against autol-
ogous HLA-I–masked mDCs was virtually undetectable com-
pared with that of activated CD56pos-derived NK cells (Fig. 3, 
B and C). These masking experiments performed on mDCs 
clearly indicate that NK cells from viremic patients are defec-
tive in their lysis of mDCs when the inhibitory eff  ects of 
MHC-I interactions with KIRs are abolished by masking the 
MHC-I molecules. Therefore, these data strongly suggest that 
the defect in iDC lysis of NK cells from viremic patients is at 
the level of the activating receptors on the NK cell itself.
Role of NKp30
The surface expression of NKp30 is decreased on fresh and 
rIL-2–activated NK cells from viremic HIV-1–infected indi-
viduals compared with cells from aviremic and uninfected 
individuals (20, 21). Therefore, we analyzed the contribution 
of NKp30 to the cytolysis of autologous iDCs in the three 
study groups. The masking of NKp30 with a specifi  c mAb 
induced a statistically signifi  cant reduction in the killing of 
iDCs by activated NK cells derived from both uninfected 
donors (P < 0.001) and HIV-1–infected patients with un-
detectable viral load (P = 0.006), confi  rming the leading role 
of NKp30 in this process (16). As expected, blocking NKp30 
Figure 4.  NK cell–mediated killing of autologous iDCs: masking of 
NKp30. (A) Autologous iDC cytolysis exerted by unfractionated rIL-2–
activated NK cells purifi  ed from a healthy donor (HD; yellow bars), an 
aviremic (green bars), and a viremic (red bars) HIV-1–infected individual. 
(B) Comparison of autologous iDC killing exerted by rIL-2–activated 
CD56pos- (dark blue bars) and CD56neg (light blue bars)-derived NK cell sub-
sets purifi  ed from the same HIV-1–infected viremic subject shown in A. 
NK cells were incubated either in the absence (baseline lysis) or presence 
of a specifi  c mAb masking NKp30. Data were obtained from single experi-
ments performed in triplicate (± SD [error bars]) and are representative of 
results obtained using cells isolated from 15 viremic and 15 aviremic HIV-
1–infected individuals and from 15 healthy donors. The NK cell/iDC ratio 
in all experiments was 10:1.2344  NK CELL–DC DEFECTIVE CROSS TALK IN HIV-1 INFECTION | Mavilio et al.
had almost no eff  ect in further reducing the already impaired 
rIL-2–activated NK cell–mediated lysis of iDCs in the cohort 
of HIV-1–infected viremic individuals because the expres-
sion of NKp30 on NK cell surfaces was already very low (20, 
21). Moreover, the masking experiments highlighted that the 
impairment in NKp30 activity was much greater in the rIL-
2–activated CD56neg-derived subset compared with the CD-
56pos-derived NK cell subset (Fig. 4). The reduced ability of 
the CD56neg NK cell subset to lyse autologous iDCs corre-
lated well with its weak NKp30 surface expression (23).
It has been reported that the secretion of IL-15 and -12 
by mDCs normally plays an important role in triggering 
the activation of autologous NK cells (7). Unlike IL-12, 
the production of IL-15 by mDCs did not substantially diff  er 
among the three study groups, prompting us to test whether 
NK cells stimulated in vitro with rIL-15 had an increased 
NKp30 surface expression and NKp30-dependent killing 
of autologous iDCs. As shown in Fig. S3 (available at http://
www.jem.org/cgi/content/full/jem.20060894/DC1), NK cells 
cultured in the presence of rIL-15 did not show any con-
siderable  increase in NKp30 surface expression on either 
CD56pos or CD56neg NK cell subsets compared with freshly 
purifi   ed and rIL-2–activated cells from HIV-1–infected 
  viremic individuals. In contrast, both rIL-2– and -15–
  activated NK cells expressed markedly higher levels of 
NKp30 compared with freshly purifi  ed NK cells from ei-
ther HIV-1–infected aviremic patients or normal donors. 
Consistent with the similar expression of NKp30 on both rIL2– 
and -15–activated NK cells from each donor within the three 
study groups, we did not observe diff  erences in the NKp30-
dependent killing of autologous iDCs between rIL-2– and -15–
activated NK cells from HIV-1–infected patients or healthy 
donors (Fig. S4).
Role of TRAIL
TNF-related apoptosis-inducing ligand (TRAIL) is a mem-
ber of the TNF ligand family that signals apoptosis via the 
death domain–containing receptors TRAIL-R1 (DR4) and 
Figure 5.  TRAIL expression and s-TRAIL secretion by rIL-2–
  activated NK cells. (A) Surface expression of TRAIL by NK cells in 
  representative examples for a healthy donor, an aviremic, and a viremic 
HIV-1–infected individual and on CD56pos and CD56neg NK cell subsets 
purifi  ed from the same HIV-1–infected viremic subject. Histogram 
graphs show the percentage and geometric mean fl  uorescence intensity 
(MFI) of freshly purifi  ed (blue lines) and rIL-2–activated (red lines) cells. 
Gray shaded histograms represent the negative controls stained with 
the second reagent alone. (B and C) Summary graphs of statistical dot 
plots with medians (horizontal bars) showing the percentages of unfrac-
tionated rIL-2 NK TRAILpos cells purifi  ed from healthy donors (yellow 
circles), aviremic (green circles), and viremic (red circles) HIV-1–infected 
patients and from rIL-2–activated CD56pos (dark blue circles) and the 
CD56neg (light blue circles)-derived NK cell subsets purifi  ed from viremic 
HIV-1–infected individuals. (D and E) Levels of sTRAIL secreted by un-
fractionated rIL-2–activated NK cells purifi  ed from healthy donors 
(yellow bar), HIV-1–infected aviremic (green bar), and viremic subjects 
(red bar) and by rIL-2–activated CD56pos- (dark blue bar) and CD56neg 
(light blue bar)-derived NK cell subsets purifi  ed from viremic HIV-1–
infected individuals. Data are presented as the median ± SD (error bars) 
of experiments conducted on 15 healthy donors and 15 HIV-1 viremic 
and aviremic infected patients.JEM VOL. 203, October 2, 2006  2345
ARTICLE
TRAIL-R2 (DR5). It is primarily expressed as a type II 
membrane protein and is also secreted in a soluble form 
(sTRAIL) only by activated T and NK cells. Moreover, in 
the mouse system, TRAIL contributes substantially to NK 
cell–mediated killing of iDCs in vivo and plays an important 
role in antiviral responses (37, 38). Therefore, we analyzed 
the surface expression and secretion of TRAIL from NK cells 
stimulated with rIL-2 for 6 d. The percentage of TRAILpos 
NK cells and the amount of sTRAIL released in the culture 
supernatant did not substantially diff   er between HIV-1–
  infected aviremic patients and healthy donors. In contrast, both 
the levels of TRAIL surface expression and sTRAIL secre-
tion were highly reduced in NK cells from HIV-1–infected 
viremic patients compared with healthy controls. Moreover, 
within the cohort of viremic HIV-1–infected individuals, the 
frequency of rIL-2–activated NK cells expressing TRAIL 
was markedly lower in the CD56neg subpopulation compared 
with the CD56pos subset. Furthermore, the concentration 
of sTRAIL in the culture supernatant of rIL-2–stimulated 
CD56neg NK cells was considerably lower compared with 
that from activated CD56pos cells (Fig. 5). 
To understand whether the decreased expression/secre-
tion of TRAIL by activated NK cells from viremic subjects 
aff  ects NK cell function in the context of the elimination of 
autologous iDCs, we repeated the masking experiments using 
a specifi  c anti-TRAIL mAb. Blocking TRAIL induced a sta-
tistically substantial reduction of the NK cell–mediated iDC 
cytolysis in both HIV-1–infected patients with undetectable 
viral load and healthy donors, which is in line with the high 
percentage of NK cells expressing and secreting TRAIL. In 
contrast, among viremic individuals, blocking TRAIL had al-
most no eff  ect in further reducing the already low cytolysis of 
iDCs by NK cells. Again, this correlated with the low levels 
of TRAIL expression and secretion by NK cells isolated from 
Figure 6.  NK cell–mediated killing of autologous iDCs: masking 
of TRAIL and NKp30. (A) Autologous iDC cytolysis exerted by unfrac-
tionated rIL-2–activated NK cells purifi  ed from a healthy donor (HD), an 
aviremic, and a viremic HIV-1–infected individual. NK cells were incu-
bated either in the absence (baseline lysis; red bars) or presence of a 
mAb-neutralizing TRAIL (pink bars). Experiments were also performed 
masking the effectors with an anti-NKp30–specifi  c mAb either in the 
absence (blue bars) or presence (purple bars) of a specifi  c anti-TRAIL 
mAb. (B) Comparison of autologous iDC killing exerted by rIL-2–activated 
CD56pos- and CD56neg-derived NK cell subsets purifi  ed from the same 
HIV-1–infected viremic subject shown in A. Cells were incubated either in 
the absence (baseline lysis; green bars) or presence of a mAb-neutralizing 
TRAIL (light blue bars). Experiments were also performed masking the 
effectors with an anti-NKp30–specifi  c mAb either in the absence (black bars) 
or presence (gray bars) of a specifi  c anti-TRAIL mAb. (C) Autologous 
  cytolysis of iDCs exerted by unfractionated rIL-2–activated NK cells from 
a representative healthy donor, an HIV-1–infected aviremic and viremic 
individual (bars on the left side of the arrow), and by CD56pos- and 
CD56neg-derived NK cell subsets purifi  ed from the same viremic patient 
(bars on the right side of the arrow). NK cells were incubated either in 
the absence (baseline lysis; red bars) or presence of a specifi  c mAb-
  neutralizing DNAM-1 (purple bars). Experiments were also performed 
masking the effectors with anti-NKp30, anti-TRAIL, and DNAM-1 mAbs 
together (yellow bars). Data were obtained from single experiments per-
formed in triplicate (± SD [error bars]) and are representative of results 
obtained using cells isolated from 15 viremic and 15 aviremic HIV-1–
infected individuals and from 15 healthy donors. The NK cell/iDC ratio in 
all experiments was 10:1.2346  NK CELL–DC DEFECTIVE CROSS TALK IN HIV-1 INFECTION | Mavilio et al.
this study group. Even the simultaneous masking of TRAIL 
and NKp30 did not result in any substantial reduction of iDC 
cytolysis by NK cells isolated from viremic patients, whereas 
the concomitant blocking of NKp30 and TRAIL virtually 
eliminated the NK cell–mediated lysis of autologous iDCs in 
the cohorts of HIV-1–infected aviremic individuals and 
healthy donors. Moreover, the impairment of TRAIL activ-
ity was much greater among the activated CD56neg-derived 
NK cells compared with the CD56pos-derived NK cell subset 
either in the absence or presence of NKp30 masking (Fig. 6, 
A and B). This refl  ected the negative or very low surface ex-
pression and secretion of TRAIL from the rIL-2–stimulated 
CD56neg NK cell subset. Finally, we detected similar DR4 
and DR5 expression on the surface of iDCs generated from 
viremic and aviremic infected patients compared with iDCs 
of healthy donors (unpublished data).
Role of DNAM-1
The aforementioned masking experiments clearly confi  rmed 
the crucial role of NKp30 in the NK cell–mediated lysis of 
autologous iDCs in healthy donors and in aviremic HIV-1–
infected subjects. Moreover, they also delineated the substan-
tial contribution of TRAIL to autologous iDC elimination by 
human activated NK cells purifi  ed from the same study groups. 
In contrast, the function of both of these molecules appeared 
to be highly impaired in NK cells isolated from viremic 
HIV-1–infected subjects. Nevertheless, NK cells from this lat-
ter cohort still exerted a considerable level of residual iDC cyto-
lysis (Fig. 6 A). Therefore, we investigated the role of another 
activating NK cell receptor,  DNAM-1, which contributes to 
the NK cell–mediated killing of iDCs (39). The addition of a 
blocking mAb specifi  c for DNAM-1 together with TRAIL 
and NKp30 reduced the lysis of autologous iDCs by unfrac-
tionated NK cells or NK cell subsets purifi  ed from viremic 
patients to almost undetectable levels (Fig. 6 C). Moreover, 
only in this latter cohort of patients, the masking of DNAM-1 
alone similarly reduced the NK cell–mediated lysis of autolo-
gous iDCs to levels comparable with those achieved by simul-
taneously blocking NKp30, TRAIL, and DNAM-1. This 
phenomenon demonstrated the compensatory role of DNAM-
1 in iDC lysis among HIV-1–infected viremic patients. In this 
regard, unlike NKp30 and TRAIL, DNAM-1 was expressed 
at normal levels on all NK cell subpopulations isolated from 
viremic subjects (unpublished data), which is in line with its 
conserved functional activity. Moreover, similar levels of 
  expression of poliovirus receptor (CD155) and Nectin-2 
(CD112), the two natural ligands for DNAM-1 (39), were 
detected on the surface of iDCs generated from all three study 
groups (unpublished data).
D  I  S  C  U  S  S  I  O  N 
This study demonstrates that numerous components of the 
bidirectional NK–DC cross talk between a CD56neg subset of 
NK cells and autologous DCs is highly impaired in cells from 
viremic HIV-1–infected individuals compared with those 
from healthy donors and aviremic HIV-1–infected individu-
als who have been receiving ART for 2 yr or longer. As il-
lustrated in the in vitro model proposed in Fig. S5 (available 
at http://www.jem.org/cgi/content/full/jem.20060894/
DC1), actively replicating HIV-1 in peripheral tissue is asso-
ciated with a markedly dysfunctional maturation of DCs, al-
though these DCs appear to be phenotypically mature on the 
basis of the expression of several costimulatory markers and 
MHC class I and II molecules. These abnormally matured 
DCs are substantially impaired in their ability to secrete IL-10 
and -12 and to prime the proliferation of neighboring autolo-
gous NK cells, which, in turn, fail to secrete adequate amounts 
of IFN-γ. It has been previously reported that NK cells from 
HIV-1–infected individuals are defective in eliminating au-
tologous iDCs (18). In this study, we show that NK cells 
  purifi  ed from HIV-1–infected individuals with high levels of 
ongoing viral replication but not from aviremic patients are 
also markedly impaired in their ability to eliminate autolo-
gous iDCs. This phenomenon is largely caused by the high 
frequency of a dysfunctional CD56neg NK cell subset, whose 
surface expression/secretion and function of NKp30 and 
TRAIL molecules are either extremely low or absent.
Under physiological conditions, the maturation of DCs is 
induced directly by microbial signals as well as by activated 
NK cells performing a regulatory role (12). Consistent with 
our results, several studies have demonstrated that in vitro 
exposure of iDCs to various isolates of HIV-1 or HIV-1 en-
velope interferes with the complete functional maturation of 
DCs, although the surface expression of markers associated 
with the DC mature phenotype is not aff  ected (28–30). We 
show here that the secretion of IFN-γ, a potent inducer of 
DC diff  erentiation (3), is highly impaired when NK cells are 
exposed to autologous mDCs generated from viremic but 
not aviremic HIV-1–infected individuals. It was recently 
demonstrated that the ability to promote DC maturation 
was essentially confi  ned to NK cells expressing a KIRneg/
NKG2Adull/NKp30pos phenotype (40). We previously re-
ported that freshly purifi  ed NK cells from HIV-1 viremic in-
dividuals expressed increased levels of KIRs, whereas they 
expressed extremely low or negative levels of NKG2A and 
NKp30 (20), particularly among the CD56neg NK cell subset 
(23). Given the association of these defects with the viremic 
state, together, these data suggest that HIV-1 directly or indi-
rectly negatively interferes with the maturation process of 
DCs. In this regard, it remains to be determined whether the 
reduced NK cell activation, as observed in vitro in this study, 
plays a role in generating functionally impaired myeloid or 
plasmacytoid DCs freshly isolated from HIV-1–infected vire-
mic patients as previously reported (27).
The priming of NK and T cells by autologous mDCs 
represents two fundamental steps in the natural process that 
links the innate to the adaptive immune response (1, 2, 4–6). 
In this study, autologous mDCs generated from viremic 
HIV-1–infected subjects clearly exhibited a markedly im-
paired capacity to induce both NK cell expansion and the se-
cretion of IFN-γ. IL-12 is an important cytokine for the 
activation and proliferation of NK cells (7–9, 32). Thus, the JEM VOL. 203, October 2, 2006  2347
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reduced IL-12 production by mDCs generated from viremic 
HIV-1–infected individuals, as demonstrated in this study, 
may partially account for their defective priming of NK cells. 
In this regard, others have previously reported that MDDCs 
that had been infected in vitro with HIV-1 fail to produce 
IL-12 in response to CD40 ligand stimulation (29).
Here, we demonstrate that mDCs generated from HIV-
1–infected viremic individuals secreted a markedly lower 
amount of IL-10 compared with mDCs from aviremic pa-
tients. Although not addressed directly in this study, the 
lower secretion of IL-10, an HIV-1 inhibitory cytokine in 
most systems (41, 42), by mDCs as well as the reduced cyto-
lytic activity of NK cells (20, 21) from HIV-1–infected vire-
mic patients may impair the inhibition of HIV-1 replication 
in peripheral tissues. Furthermore, it has been shown that 
IL-10 inhibits the expression of DC costimulatory molecules 
(43), and, therefore, the weak production of IL-10 by mDCs 
generated from viremic HIV-1–infected individuals may 
partly contribute to the mature phenotype of the markedly 
dysfunctional mDCs.
Whether DCs from HIV-1–infected individuals are also 
impaired in their ability to prime an eff  ective T cell response 
remains controversial (44). Nevertheless, several studies have 
reported a highly impaired capacity to activate autologous 
and heterologous T cells either by in vitro HIV-1–exposed 
mDCs generated from healthy individuals or by myeloid or 
plasmacytoid DCs freshly isolated from HIV-1–infected vire-
mic individuals (27, 28, 45). Moreover, the in vitro observa-
tion that iDCs exposed to HIV-1 achieve an mDC phenotype, 
express high amounts of CCR7, and are able to chemotax in 
response to MIP-3β (CCL19) indicates that they are able to 
migrate to secondary lymphoid tissues, where they can par-
ticipate in the priming of T cells (30). It has also been shown 
in vitro and ex vivo that these phenotypically mature but 
functionally immature DCs are infected by HIV-1 (46, 47) 
and are also able to transmit the virus to autologous T cells 
(30, 47, 48). Collectively these data suggest that these pheno-
typically mature but dysfunctional DCs would generate a 
suboptimal adaptive T cell response and might also be able to 
spread the infection.
A potentially important mechanism through which NK 
cells are thought to impact the quality of DCs undergoing 
maturation in response to antigen uptake is by killing iDCs 
(1, 2, 4–6). It is likely that this phenomenon occurs primarily 
at sites of tissue infl  ammation and appears to be dependent on 
the NK cell/DC ratio (1, 2, 5, 6). Low ratios of NK cells/
DCs lead to DC survival and maturation, whereas high ratios 
of NK cells/DCs result in the elimination of DCs and the in-
hibition of DC maturation (17). A recent study showed that 
iMDDCs generated from HIV-1–infected patients can escape 
lysis by autologous NK cells (18), but the underlying causes 
of this escape have not been identifi  ed. We address some of 
the cellular mechanisms that may account for impaired NK 
cell–mediated lysis of autologous iDCs and show that this 
phenomenon appears to be restricted to those HIV-1–
  infected individuals with persistent high viremia. Our data 
demonstrate that the markedly impaired expression/secretion 
and function of NKp30 and TRAIL largely account for the 
highly defective NK cell–mediated lysis of autologous iDCs 
generated from viremic HIV-1–infected subjects. Moreover, 
we show that within this study group, the overrepresentation 
of CD56neg NK cells expressing the unusual KIRpos/NK-
G2Aneg/NKp30neg/TRAILneg phenotype (23), a subset pres-
ent at very low frequencies in aviremic HIV-1–infected 
patients as well as in healthy donors (20), likely explains why 
this defective elimination of autologous iDCs by NK cells is 
confi  ned to HIV-1–positive viremic patients.
DCs are distributed within all lymphoid and nonlym-
phoid tissues and in humans are classifi  ed into at least two 
major types, myeloid and plasmacytoid, which diff  er in terms 
of function and phenotype (49). Plasmacytoid DCs, regard-
less of their state of diff  erentiation/activation, are poorly sus-
ceptible to NK cell–mediated lysis (12) and do not effi   ciently 
present antigens to T cells, whereas myeloid DCs are potent 
inducers of adaptive immunity (47, 49). It has been reported 
recently that freshly isolated myeloid DCs from healthy indi-
viduals were susceptible to NK cell–mediated lysis, although 
to a lesser degree than were iMDDCs (50). However, the 
NK cell/DC ratios found in that study were possibly too low, 
and it is conceivable that the observed diff  erences between 
freshly isolated myeloid DCs and iMDDCs with regard to 
the susceptibility to lysis may have been reduced at higher 
NK cell/DCs ratios. In addition, the heterogeneity of freshly 
isolated myeloid DCs in their surface expression of MHC-I 
molecules and costimulatory markers refl  ects diff  erences in 
the maturation or activation state (49, 50) and, therefore, may 
impact NK cell–mediated killing. Although MDDCs diff  er 
from freshly isolated myeloid DCs in certain respects, previ-
ous studies have found that MDDCs are very similar both 
phenotypically and functionally to myeloid DCs present in 
the blood (47, 49). Therefore, we feel that MDDCs are ap-
propriate surrogates for freshly isolated myeloid DCs and 
represent a practical tool in vitro for investigating the role of 
NK–DC cross talk in the pathogenesis of human diseases.
The conserved numbers and phenotype of circulating 
monocytes among viremic patients compared with aviremic 
and healthy subjects (unpublished data) are consistent with 
previous studies showing that a very small proportion of 
blood monocytes harbor HIV-1 throughout the course of 
infection (51, 52). Nonetheless, it has been demonstrated that 
the infection of monocytes with HIV-1 can aff  ect important 
functions of monocytes, such as chemotaxis and phagocytic 
capacity, suggesting that viral replication in monocytes/ 
macrophages may contribute to the establishment and persis-
tence of HIV-1 infection and may also activate and infect 
surrounding T cells (51, 52).
In summary, certain bidirectional NK–DC interactions 
that normally occur after an infl  ammatory insult are aff  ected 
during HIV-1 infection, resulting in the abnormal maturation 
of DCs, impaired activation of NK cells, and defi  cient killing 
of unnecessary iDCs by NK cells. As demonstrated in this 
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CD56neg subset of NK cells observed only in viremic and not 
in aviremic HIV-1–infected individuals or normal controls. 
Additional studies will be needed to verify the in vivo signifi  -
cance of this markedly defective NK–DC cross talk among 
cells from HIV-1–infected viremic individuals to fully appre-
ciate the potential negative impact on the immune-mediated 
control of HIV-1.
MATERIALS AND METHODS
Study subjects. Two cohorts of 15 viremic and 15 aviremic HIV-1–in-
fected patients were studied (Table S1, available at http://www.jem.org/
cgi/content/full/jem.20060894/DC1). The viremic group was composed 
of HIV-1–infected individuals who were either naive to therapy or had for-
merly been receiving ART but whose treatment regimen had been discon-
tinued at the time of our study. The aviremic group had been receiving 
ART for at least 24 mo, and viremia remained undetectable over this time 
period. PBMCs were obtained by leukapheresis performed after obtaining 
signed consent forms and in accordance with clinical protocols approved by 
the Institutional Review Board (IRB) of the University of Toronto (13 pa-
tients) and of the National Institute of Allergy and Infectious Diseases 
(NIAID; 17 patients). As negative controls, PBMCs from 15 healthy donors 
seronegative for HIV-1 were obtained by apheresis provided by the Transfu-
sion Medicine Department of the Mark O. Hatfi  ed Clinical Research Cen-
ter National Institutes of Health as a part of IRB-approved clinical studies 
(Table S1). All experiments performed in this study using cells derived from 
HIV-1–infected individuals and from healthy donors have been approved by 
the IRBs of the University of Toronto and the NIAID.
Isolation and culture of NK cells and generation of MDDCs. PBMCs 
were isolated over Ficoll-Hypaque gradients (lymphocyte separation me-
dium; MP Biomedicals). NK cells were freshly isolated by negative selection 
(StemCell Technologies Inc.; reference 20). Purifi  ed NK cells contained 
≤3% contamination with other PBMC subsets as determined by the expres-
sion of CD3, TCR-α/β, TCR-γ/δ, CD19, or CD14. CD56pos or CD56neg 
NK cell subsets were separated by a magnetic cell-sorting technique (Milte-
nyi Biotec; reference 23). The purities of CD56pos or CD16neg NK cell frac-
tions were consistently >95 and 90%, respectively. Polyclonal NK cells and 
NK cell subsets were activated in vitro with recombinant IL-2 (rIL-2; 
Roche) at 200 UI/ml or with recombinant IL-15 (rIL-15; R&D Systems) at 
10 ng/ml for 6 d (23).
To generate iDCs, monocytes were isolated from PBMCs by immuno-
magnetic selection (Miltenyi Biotec). The purity of CD14pos and CD1aneg 
monocytes was ≥98%. iMDDCs were then obtained by culturing the highly 
purifi  ed CD14pos cells at 106 cells/ml in complete media plus IL-4 at 200 U/
ml (PeproTech) and GM-CSF at 200 ng/ml (Leukine Liquid Sargramostin). 
After 6 d of stimulation in culture, CD14dim-neg and CD1apos iMDDCs were 
induced to undergo maturation by incubation with LPS at 1 μg/ml (Sigma-
Aldrich) or sCD40 liter at 2 μg/ml (Biosource International) for 24 h.
mAbs. The following mAbs were used in this study: mAbs 289 (IgG2a anti-
CD3), C218 (IgG1 anti-CD56), KD1 (IgG2a anti-CD16), Gl183 (IgG1 
anti-p58.2/KIR2DL2), 11pb6 (IgG1 anti-p58.1/KIR2DL1), Z27 (IgG1 
anti-p70/KIR3DL1), F278 (IgG1 anti-LIR1/ILT2), Z270 (IgG1 anti-
NKG2A), Xa185 (IgG1 anti-CD94), Bab281 and KL247 (IgG1 and IgM 
anti-NKp46, respectively), Az20 and F252 (IgG1 and IgM anti-NKp30, re-
spectively), Z231 and KS38 (IgG1 and IgM anti-NKp44, respectively), 
Kra236 and F5 (IgG1 and IgM anti-DNAM, respectively), L95 (IgG1 anti–
poliovirus receptor), L14 (IgG2a anti–Nectin-2), and A6-136 (IgM anti–
HLA-A/-B/-C). FITC- or PE-labeled anti-CD4 (IgG1), anti–TCR-α/β 
(IgG1), anti–TCR-γ/δ (IgG1), anti-CD19 (IgG1), anti-CD56 (IgG2b), 
anti-CD14 (IgG1), anti-CD1a (IgG1), anti-CD40 (IgG1), anti-CD80 (IgM), 
anti-CD83 (IgG1), anti-CD86 (IgG1), anti–HLA-A/-B/-C (IgG1), anti–
HLA-DP/-DQ/-DR (IgG2a), and anti-TRAIL (IgG1) were purchased 
from BD Biosciences. The anti–Trail-R1, -R2, -R3, and -R4 mAbs were 
purchased from R&D Systems, and the anti–HLA-E mAbs (IgG1) were pur-
chased from Novus Biologicals.
Flow cytometry and cytolytic activity. For one- or two-color cytofl  uo-
rimetric analysis (FACSCalibur; BD Biosciences), rIL-2–activated NK cells, 
iDCs, and mDCs were stained with the appropriate mAbs followed by PE- or 
FITC-conjugated isotype-specifi  c goat anti–mouse second reagent (Southern 
Biotechnology Associates, Inc.). Second appropriate antiisotypic mAbs stained 
with PE and/or FITC were used as negative controls. The data were analyzed 
using CellQuest software (BD Biosciences). After 6 d of activation with rIL-2, 
NK cells were tested for cytolytic activity in a 4-h Cr51 release assay as de-
scribed previously (20). Saturating concentrations (10 μg/ml) of specifi  c 
mAbs blocking NK cell receptors were added for the masking experiments 
performed with autologous iDCs. The NK cell/iDC ratio was 10:1.
Fluorescence microscopy. rIL-2–activated NK cells were stained with 
cell tracker CM-DiI (Invitrogen) and autologous iDCs with Hoechst 33342 
(Invitrogen). Fluorescent cells were coincubated for 2 h in 1640 RPMI me-
dium supplemented with 10% FCS in the presence of FLICA reagent (Invit-
rogen) on fi  bronectin-coated chamber slides (LAB-TEK) at 37°C and 5% 
CO2 atmosphere. The NK cell/iDC ratio was 10:1. NK cells and iDCs were 
then washed with PBS, suspended in medium, and sealed on the slides with 
coverslips. Snap-shot images were captured on an inverted epifl  uorescence 
microscope (Axiovert 135; Carl Zeiss MicroImaging, Inc.) equipped with a 
fi  lter for red, green, and blue dyes using a 20× plan-Apochromat objective. 
Imaris 4.04 software (Bitplane AG) was used for image processing.
NK cell proliferation assay. Freshly purifi  ed NK cells were cryopreserved 
until required as responders. Experiments were performed in triplicate in 
96-well round plates with complete medium. NK cells were cocultured at a 
constant concentration of 2 × 105 NK cells/well with autologous and heter-
ologous mMDDCs (stimulators) in serial dilutions (10–1.56 × 103 cells/
well). After 4 d, NK cell proliferation was measured by 3[H]thymidine up-
take (16 h).
Cytokine secretion. The levels of IL-12p70 (IL-12), IL-10, -15, and -18 
  secreted by mDCs and the level of sTRAIL secreted by r-IL2–activated NK 
cells were measured from cell culture supernatant by ELISA (R&D Systems 
and Biosource International). To detect the production of IFN-γ, freshly pu-
rifi  ed NK cells were cryopreserved until required and cocultured with autolo-
gous LPS or sCD40L matured DCs in 96-well round-bottom plates with 
complete medium (9). The mDC/NK cell ratio was 1:10. The supernatant of 
the cultures was collected after 24 h and assayed by ELISA (BD Biosciences).
Statistical analysis. The distributions of each immune response variable 
were compared between uninfected and HIV-1–infected viremic and avire-
mic individuals using the Mann-Whitney test. For each individual, the dif-
ferences between the CD56neg and CD56pos NK cell subsets were evaluated 
using the Wilcoxon signed ranks test. All p-values are two sided.
Online supplemental material. Fig. S1 shows the surface expression of 
maturation markers on iDCs and mDCs generated in vitro from representa-
tive donors within the three study groups. Fig. S2 shows the degree of NK 
cell–mediated lysis and CD56pos and CD56neg NK subset–mediated lysis of 
autologous iDCs from representative donors within the three study groups 
using the traditional Cr51 release assay and fl  uorescence microscopy. Fig. S3 
shows the NKp30 surface expression on freshly purifi  ed rIL-2– and -15–
  activated NK cells from representative donors within the three study groups. 
Fig. S4 shows the NKp30-dependent killing of autologous iDCs by rIL-2– 
and -15–activated NK cells from representative donors within the three 
study groups. Fig. S5 shows our proposed model of the impaired interactions 
between NK cells and DCs in HIV-1–infected viremic patients. Table S1 
provides data on the profi  les of viremic and aviremic HIV-1–infected pa-
tients and healthy donors. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20060894/DC1.JEM VOL. 203, October 2, 2006  2349
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